Tina McCartan
Adult Health · Houston, TXNPI 1114390416
Payments from drug & device makers
Across 271 payments — averaging $20.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$971
- Lilly USA, LLC$705
- Amgen$419
- Radius Health, Inc.$407
- Amneal Pharmaceuticals LLC$262
- Antares Pharma, Inc.$188
- plus $3K from 31 others
What the payments were for
- Food & beverage$5,590100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 29 | $971 |
| Lilly USA, LLC | 38 | $705 |
| Amgen | 26 | $419 |
| Radius Health, Inc. | 30 | $407 |
| Amneal Pharmaceuticals LLC | 14 | $262 |
| Antares Pharma, Inc. | 10 | $188 |
| Medtronic | 4 | $175 |
| IBSA Pharma Inc. | 10 | $174 |
| Insulet Corporation | 8 | $166 |
| Tandem Diabetes Care, Inc. | 6 | $162 |
| Boehringer Ingelheim | 10 | $160 |
| Xeris Pharmaceuticals, Inc. | 8 | $147 |
| BETA Bionics, Inc. | 5 | $146 |
| AbbVie | 9 | $143 |
| Dexcom, Inc. | 8 | $137 |
| Bayer | 7 | $133 |
| Corcept Therapeutics | 5 | $131 |
| Sanofi-aventis U.S. LLC | 6 | $129 |
| Avvisto Therapeutics, LLC | 4 | $116 |
| Neurocrine Biosciences, Inc. | 3 | $95 |
| Sequel Med Tech, LLC | 3 | $81 |
| AstraZeneca | 4 | $77 |
| Astellas Pharma US Inc | 3 | $60 |
| Mannkind Corporation | 3 | $55 |
| Merck | 2 | $46 |
| Recordati_rare_diseases_inc. | 2 | $42 |
| Cequr Corporation | 2 | $40 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $34 |
| Esperion Therapeutics, Inc. | 2 | $29 |
| Soleno Therapeutics, Inc. | 1 | $27 |
| Kyowa Kirin, Inc. | 1 | $23 |
| Halozyme Inc | 1 | $23 |
| Alvogen Inc | 1 | $22 |
| Amryt Pharma Holdings Ltd | 1 | $19 |
| Tolmar, Inc. | 1 | $18 |
| Currax Pharmaceuticals LLC | 1 | $17 |
| Acerus Pharmaceuticals Corporation | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,590 in reported general payments places this provider in the 90th percentile of 933 adult health providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 178 | $299,459 |
| FarxigaDapagliflozin Propanediol | 73 | $106,496 |
| TrulicityDulaglutide | 52 | $73,592 |
| MounjaroTirzepatide | 48 | $63,820 |
| Tresiba Flextouch U-100Insulin Degludec | 38 | $33,192 |
| JardianceEmpagliflozin | 21 | $30,622 |
| RybelsusSemaglutide | 12 | $25,886 |
| Tresiba Flextouch U-200Insulin Degludec | 22 | $23,670 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 12 | $9,371 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 11 | $6,678 |
| HumalogInsulin Lispro | 17 | $5,740 |
| Humalog Kwikpen U-100Insulin Lispro | 19 | $5,520 |
| SynthroidLevothyroxine Sodium | 40 | $3,750 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 38 | $3,619 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $2,438 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $971 | $325,345190 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Insulin Lispro | $705 | $143,945130 claims |
| AstraZenecaFarxiga | $77 | $106,49673 claims |
| Boehringer IngelheimJardiance | $160 | $30,62221 claims |
| AbbVieSynthroid | $143 | $3,75040 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $262 | $1,15794 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 933 adult health providers in Texas.
Other adult health in Houston
- Kacey LyonsHouston$20K
- Rosa RancesHouston$17K
- Claressa RosacinaHouston$17K
- Michelle MartinHouston$15K
- Loren SemonesHouston$14K
- Anthony SantosHouston$13K
- Dashawn ThomasHouston$11K
- Zandra RiveraHouston$11K
- Brandy KhodrHouston$10K
- Janice TranHouston$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.